Francesco Bertoni

Francesco Bertoni's AcademicInfluence.com Rankings

Francesco Bertoni

Biology

#12130

World Rank

#15584

Historical Rank

Biotechnology

#210

World Rank

#212

Historical Rank

Genetics

#1321

World Rank

#1423

Historical Rank

Molecular Biology

#1935

World Rank

#1966

Historical Rank

biology Degrees

Download Badge

Biology

Francesco Bertoni's Degrees

PhD Biomedical Sciences University of Milan
Masters Biotechnology University of Milan
Bachelors Biotechnology University of Milan

Why Is Francesco Bertoni Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Francesco Bertoni's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells (2005) (1219)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma (2009) (1047)
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation (2011) (643)
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. (2013) (480)
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. (2011) (388)
Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. (1997) (384)
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. (2015) (350)
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development (2012) (336)
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. (2011) (316)
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. (2011) (302)
BET Proteins as Targets for Anticancer Treatment. (2018) (268)
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. (2005) (252)
Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. (1998) (246)
Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. (2000) (236)
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. (2008) (231)
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs (2015) (220)
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma (2006) (208)
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. (2013) (204)
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. (2011) (200)
Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome (2009) (193)
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). (2005) (191)
Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. (1997) (190)
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. (2016) (186)
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. (2018) (183)
Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. (1999) (172)
The gastric marginal zone B-cell lymphoma of MALT type (2000) (166)
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. (2011) (163)
Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. (2012) (153)
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors (2009) (151)
Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases (2003) (137)
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. (2019) (135)
Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. (2009) (133)
A SNP microarray and FISH‐based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect (2009) (130)
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study (2009) (128)
The genetics of nodal marginal zone lymphoma. (2016) (125)
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). (2000) (120)
Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors (2017) (117)
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. (2014) (114)
The gastric marginal zone B-cell lymphoma of MALT type. (2000) (114)
State-of-the-art therapeutics: marginal-zone lymphoma. (2005) (112)
Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. (2002) (110)
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. (2008) (109)
Update on the molecular biology of mantle cell lymphoma (2006) (109)
Molecular basis of mantle cell lymphoma (2004) (108)
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer (2017) (108)
Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma (2007) (107)
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation (2014) (105)
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 (2009) (104)
Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia (2003) (103)
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. (2009) (101)
Dnmt3a restrains mast cell inflammatory responses (2017) (101)
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. (2013) (100)
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. (2012) (100)
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. (2009) (95)
Incidence, risk factors and outcome of histological transformation in follicular lymphoma (2012) (95)
Identification of T Cell-Restricted Genes, and Signatures for Different T Cell Responses, Using a Comprehensive Collection of Microarray Datasets1 (2005) (94)
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. (1999) (90)
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma (2010) (88)
A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression (2006) (87)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma (2012) (87)
Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. (2016) (86)
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy (2006) (83)
Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas (2014) (81)
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study (2019) (80)
Histologic transformation in marginal zone lymphomas†. (2015) (80)
Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. (2014) (79)
The cellular origin of mantle cell lymphoma. (2007) (79)
13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia (2011) (78)
Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. (1998) (77)
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. (2005) (75)
Marginal zone lymphomas. (2008) (75)
Gela histological scoring system for post‐treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice (2013) (74)
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus (2016) (72)
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia (2013) (72)
Genome‐wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion (2008) (72)
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T‐cell infiltration and positioning of malignant B cells (2010) (72)
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy (2017) (71)
Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland. (2000) (70)
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma (2014) (69)
B‐Cell Chronic Lymphocytic Leukaemia (2011) (68)
Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease (2007) (68)
Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. (2001) (68)
Oncogenic BARD1 isoforms expressed in gynecological cancers. (2007) (64)
Bayesian DNA copy number analysis (2009) (63)
MALT lymphomas: pathogenesis can drive treatment. (2011) (63)
Reactive perivascular T‐cell infiltrate predicts survival in primary central nervous system B‐cell lymphomas (2007) (62)
Genetic lesions in diffuse large B-cell lymphomas. (2015) (60)
Delving deeper into MALT lymphoma biology. (2005) (60)
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma (2014) (59)
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. (2015) (58)
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers (1999) (57)
Comparative genome‐wide profiling of post‐transplant lymphoproliferative disorders and diffuse large B‐cell lymphomas (2006) (56)
Genomic lesions associated with a different clinical outcome in diffuse large B‐Cell lymphoma treated with R‐CHOP‐21 (2010) (55)
Genome wide DNA‐profiling of HIV‐related B‐cell lymphomas (2010) (55)
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance (2009) (51)
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B‐cell lymphomas (2010) (51)
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia (2019) (50)
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. (2015) (50)
Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features (2010) (50)
Single nucleotide polymorphism‐arrays provide new insights in the pathogenesis of post‐transplant diffuse large B‐cell lymphoma (2010) (50)
Genome‐wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia (2011) (49)
Cellular, Molecular Consequences of Peroxisome Proliferator- Activated Receptor-δ Activation in Ovarian Cancer Cells (2006) (49)
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes (2020) (49)
Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides (2018) (48)
Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process (1997) (48)
Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP (2011) (48)
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. (2013) (47)
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses (2019) (46)
PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas (2015) (46)
Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature (1998) (46)
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL. (2015) (45)
Anaplastic lymphoma kinase in human cancer. (2011) (44)
The NF-B negative regulator TNFAIP 3 ( A 20 ) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas (2009) (44)
Genomic profiles of MALT lymphomas: variability across anatomical sites (2011) (43)
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas (2015) (43)
MYD88 somatic mutations in MALT lymphomas (2012) (42)
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. (2017) (42)
The strength of T cell stimulation determines IL‐7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL‐7Rhi T cells (2008) (40)
Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. (2008) (40)
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation (2014) (40)
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations (2016) (39)
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. (2019) (38)
Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia (2005) (37)
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia (2011) (37)
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease (2018) (37)
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma (2017) (37)
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. (2008) (36)
Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients (2007) (36)
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence (2016) (36)
Splenic marginal zone lymphoma: current knowledge and future directions. (2012) (36)
Recent advances in understanding the biology of marginal zone lymphoma (2018) (34)
Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma. (2012) (34)
Patterns of survival of follicular lymphomas at a single institution through three decades (2010) (34)
Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types (2020) (33)
B‐cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage (2011) (33)
The management of nongastric MALT lymphomas. (2014) (33)
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified (2019) (33)
Chromosome band 6q deletion pattern in malignant lymphomas. (2006) (33)
PCSF: An R-package for network-based interpretation of high-throughput data (2017) (32)
The Essentials of Marine Biotechnology (2021) (32)
Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. (2007) (32)
Risk factors of central nervous system relapse in mantle cell lymphoma (2013) (32)
High density genome‐wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia (2008) (32)
Life expectancy of young adults with follicular lymphoma. (2015) (31)
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (2004) (31)
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents (2019) (30)
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells (2016) (30)
An overview on anti-tubulin agents for the treatment of lymphoma patients. (2020) (29)
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response (2014) (29)
A New Network for the Advancement of Marine Biotechnology in Europe and Beyond (2020) (29)
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis (2011) (29)
Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas (2011) (28)
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias (2018) (28)
Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas (2000) (28)
Targeting BET bromodomain proteins in cancer: The example of lymphomas. (2020) (28)
Diffuse large B‐cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome (2011) (28)
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. (1999) (28)
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia (2012) (27)
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. (2006) (26)
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. (2021) (26)
Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells (2010) (25)
IgVH mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome (2005) (25)
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas (2007) (25)
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma (2019) (25)
Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma (2015) (24)
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. (2007) (24)
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. (2016) (24)
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. (2020) (24)
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma (2019) (23)
Disruption of BIRC 3 associates with fludarabine chemorefractoriness in TP 53 wild-type chronic lymphocytic leukemia (23)
T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways (2018) (23)
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas (2018) (23)
BCL10 gene mutations rarely occur in lymphoid malignancies (2000) (23)
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. (2020) (23)
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma? (2020) (23)
Bayesian network data imputation with application to survival tree analysis (2016) (22)
An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens (2012) (22)
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes (2016) (22)
Immunogenetics features and genomic lesions in splenic marginal zone lymphoma (2010) (22)
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer (2020) (22)
Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype (2012) (22)
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models (2019) (21)
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma (2016) (21)
Molecular and transcriptional characterization of the novel 17p11.2‐p12 amplicon in multiple myeloma (2007) (21)
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance (2018) (20)
The genetic landscape of dural marginal zone lymphomas (2016) (20)
Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach (1998) (20)
Promoter methylation patterns in Richter syndrome affect stem‐cell maintenance and cell cycle regulation and differ from de novo diffuse large B‐cell lymphoma (2013) (20)
Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. (1997) (20)
Genome‐wide high resolution DNA profiling of hairy cell leukaemia (2013) (19)
Prognostic impact of monocyte count at presentation in mantle cell lymphoma (2013) (19)
Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736 (2015) (19)
Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency‐related non‐Hodgkin lymphomas (2011) (19)
Prognostic models for diffuse large b‐cell lymphoma (2000) (19)
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma (2013) (19)
A novel phage display based platform for exosome diversity characterization. (2022) (19)
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. (2020) (18)
Toward new treatments for mantle-cell lymphoma? (2013) (18)
Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. (1999) (18)
DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas (2019) (17)
Management of rare forms of lymphoma (1998) (17)
An integrated Bayesian analysis of LOH and copy number data (2010) (17)
Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature (1997) (17)
Primary extranodal lymphoma of skeletal muscles: a report of four cases. (1998) (16)
Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. (1999) (16)
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. (2012) (16)
Microsatellite instability in gastric MALT lymphomas and other associated neoplasms. (1999) (16)
Treatment of gastric marginal zone lymphoma of MALT type (2010) (15)
Long‐term therapeutic efficacy and toxicity of recombinant interferon‐alpha 2a in polycythaemia vera (1998) (15)
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes (2012) (15)
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. (2013) (15)
Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation (2018) (15)
Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq (2019) (15)
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. (2021) (15)
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma (2018) (15)
Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa? (2006) (14)
Staining the target: CD37 expression in lymphomas. (2016) (14)
Genome-wide DNA profiling of HIV-related B-cell lymphomas. (2013) (14)
The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes (2014) (14)
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas. (2022) (14)
Genome-wide promoter methylation of hairy cell leukemia. (2019) (14)
ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. (2017) (14)
Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. (1999) (14)
Allelic expression of p73 in human ovarian cancers. (1999) (13)
The involvement of microRNA in the pathogenesis of Richter syndrome (2018) (13)
Mantle cell lymphoma (2004) (13)
The clinical and biological features of a series of immunophenotypic variant of B‐CLL (2010) (13)
Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. (1997) (13)
Chromosome instability and translocation t(11;18) in primary gastric marginal zone B‐cell lymphoma of MALT‐type (2007) (13)
Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma (2021) (13)
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents (2019) (13)
Absence of NOTCH1 gene mutations in MALT lymphomas (2012) (13)
Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia (2014) (12)
Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor (2014) (12)
Clonality assessment in blood of patients with mantle cell lymphoma. (1999) (12)
The transcription factor ETS1 in lymphomas: friend or foe? (2015) (12)
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array (2012) (12)
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP‐319 in pre‐clinical models of aggressive lymphomas (2019) (12)
Integrated profiling of diffuse large B‐cell lymphoma with 7q gain (2011) (12)
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax (2019) (11)
First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies. (2018) (11)
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. (2020) (11)
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity (2021) (11)
Genetic alterations in systemic nodal and extranodal non‐cutaneous lymphomas derived from mature T cells and natural killer cells (2012) (11)
Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma (2008) (11)
The changing paradigm of chronic lymphocytic leukemia management. (2013) (11)
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines (2019) (11)
A Fast Prize-Collecting Steiner Forest Algorithm for Functional Analyses in Biological Networks (2017) (11)
Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices (2013) (10)
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort (2010) (10)
PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients (2021) (10)
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. (2019) (10)
Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization (2019) (10)
Genetic lesions in diffuse large B-cell lymphomas. (2015) (10)
Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. (2011) (10)
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. (2021) (10)
Pixantrone: novel mode of action and clinical readouts (2018) (9)
The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years (2011) (9)
Association of gastric and Waldeyer's ring lymphoma: a molecular study (2000) (9)
Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. (2020) (9)
Methylation patterns in marginal zone lymphoma. (2017) (9)
Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy (2017) (8)
Mantle cell lymphoma: new treatments targeted to the biology. (2002) (8)
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond (2020) (8)
Another Piece of the MALT Lymphomas Jigsaw. (2005) (8)
Pathogenesis and treatment of extranodal lymphomas: the fascinating model of mucosa-associated lymphoid tissue lymphoma. (2003) (8)
Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma (2012) (8)
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03 (2009) (8)
Genetic alterations underlying the pathogenesis of MALT lymphoma. (2002) (8)
Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma. (2000) (8)
RP6530, a Dual PI3Kδ/γ Inhibitor, Attenutates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) Cells (2013) (8)
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines (2018) (7)
Primary central nervous system lymphoma: Novel precision therapies. (2019) (7)
DNA Copy Number Changes in Diffuse Large B Cell Lymphomas (2020) (7)
HMGA1-pseudogene7 transgenic mice develop B cell lymphomas (2020) (7)
Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis (2013) (7)
Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. (2020) (7)
Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. (1996) (7)
Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines (2000) (7)
STAT6 activation correlates with cerebrospinal fluid IL‐4 and IL‐10 and poor prognosis in primary central nervous system lymphoma (2020) (7)
Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event? (1997) (7)
Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models (2019) (7)
528 The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL) (2012) (6)
BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL) (2011) (6)
ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration (2017) (6)
Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells (2013) (6)
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1–2 study (2018) (6)
Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. (2011) (6)
cuRnet: an R package for graph traversing on GPU (2018) (6)
The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL) (2012) (6)
Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance (2019) (5)
The novel BTK and PI3K-delta inhibitors acalabrutinib (ACP-196) and ACP-319 show activity in pre-clinical B-cell lymphoma models (2016) (5)
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma (2019) (5)
Abstract A179: The BRD4 degrader MZ1 exhibits potent antitumoral activity in diffuse large B cell lymphoma of the activated B cell-like type (2018) (5)
KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells (2021) (5)
Identi fi cation of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB 4 transcripts (2015) (5)
The novel atypical retinoid ST5589 down‐regulates Aurora Kinase A and has anti‐tumour activity in lymphoma pre‐clinical models (2015) (5)
Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach (2018) (5)
Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas (2008) (5)
Evaluation of [1,2]oxazolo[5,4-e]isoindoles in lymphoma cells (2020) (5)
OmicsNet: Integration of Multi-Omics Data using Path Analysis in Multilayer Networks (2017) (5)
HMGA1 induces EZH2 overexpression in human B-cell lymphomas. (2021) (4)
REAL-TIME LUNG TUMOUR MOTION MODELING FOR ADAPTIVE RADIATION THERAPY USING LEGO MINDSTORMS (2015) (4)
TP53 Mutations, the Most Frequent Genetic Lesion in Richter Syndrome, Represent An Independent Predictor of Survival Post Transformation. (2009) (4)
Abstract 4182: The two novel BTK-inhibitors M2951 and M7583 show in vivo anti-tumor activity in pre-clinical models of B cell lymphoma (2017) (4)
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer (2017) (4)
The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL) (2017) (4)
Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
Abstract B77: The BET bromodomain inhibitor OTX015 (MK-8628) in mantle cell lymphoma (MCL): in vivo activity and identification of novel combinations to overcome adaptive resistance (2015) (4)
Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers (2011) (4)
TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line (2018) (4)
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified (2019) (4)
Abstract 5531: OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma (2014) (4)
Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. (2022) (4)
The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents (2016) (4)
Let's give BACH2 a breath of fresh air. (2017) (4)
Abstract 3853: Humanized NOD/Scid/IL2g-/- tumor grafts recapitulate primary anaplastic large cell lymphoma. (2013) (4)
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES (2019) (4)
Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors (2018) (4)
A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals (2007) (3)
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. (2012) (3)
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR‐ABL inhibitors in lymphomas (2011) (3)
Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents (2015) (3)
DNA fingerprinting of low-grade extranodal marginal zone B-cell lymphoma (of MALT type) (1999) (3)
LYMPHOID NEOPLASIA PRDM 1 / BLIMP 1 is commonly inactivated in anaplastic large T-cell lymphoma (2013) (3)
SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS (2019) (3)
Population‐based outcome analysis of diffuse large B‐cell lymphoma in people living with HIV infection and competent individuals (2018) (3)
Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models (2015) (3)
The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors (2012) (3)
Cellular and Molecular Consequences of Peroxisome Proliferator– Activated Receptor- ; Activation in Ovarian Cancer Cells 1 * (2006) (3)
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer (2018) (3)
Analysis of BCL-10 gene mutations in ovarian cancer cell lines. (1999) (3)
Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor (2015) (3)
THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION (2019) (3)
Abstract 154: The phosphatidylinositol-3-kinase (PI3K) inhibitor (i) copanlisib is active in preclinical models of B-cell lymphomas as single agent and in combination with conventional and targeted agents including venetoclax and palbociclib (2017) (3)
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma (2020) (3)
Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma (2016) (3)
Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma (2021) (3)
Abstract B061: Targeting lymphomas with the novel first-in-class pan-NOTCH transcription inhibitor CB-103 (2018) (3)
RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis (2021) (3)
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas (2021) (3)
Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529 (2016) (3)
Abstract A127: Secretion of IL16 is associated with resistance to ibrutinib in pre-clinical models of lymphoma (2019) (3)
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis (2022) (3)
Syk expression patterns differ among B-cell lymphomas. (2010) (3)
Erratum to Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma [Cancer Cell 27, 516-532] April 13, 2015 10.1016/j.ccell.2015.04.014 (2015) (3)
Pathobiology and molecular basis of MALT lymphoma (2008) (3)
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas (2019) (3)
ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma (2021) (3)
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type (2020) (3)
Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades (2022) (3)
Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies. (2019) (2)
Hierarchy of Human B Cell Regeneration after Rituximab Therapy. (2006) (2)
Chapter 21 – Marginal Zone B-Cell Lymphomas (2006) (2)
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors (2022) (2)
Indolent lymphoma 295 ANALYSIS OF PROGNOSTIC FACTORS IN 424 MALT LYMPHOMA PATIENTS TREATED IN THE IELSG-19 MULTICENTER RANDOMISED STUDY (2011) (2)
Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways (2016) (2)
Marginal Zone Lymphomas. (2020) (2)
Non‐negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms (2010) (2)
Abstract A119: The BET-bromodomain inhibitor OTX015 shows synergism with several anticancer agents in preclinical models of diffuse large B-cell lymphoma (DLBCL). (2013) (2)
Abstract PO-46: Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma (2020) (2)
Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia (2022) (2)
COPANLISIB SYNERGIES WITH CONVENTIONAL AND TARGETED AGENTS INCLUDING VENETOCLAX IN PRECLINICAL MODELS OF B‐ AND T‐CELL LYMPHOMAS (2019) (2)
The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications (2021) (2)
Abstract A219: OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. (2013) (2)
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences (2022) (2)
Fast and Robust Segmentation of Copy Number Profiles Using Multi-Scale Edge Detection (2016) (2)
Lymphoma: MALT and other marginal zone lymphomas (2013) (2)
Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion. (2007) (2)
Extranodal Marginal Zone B-Cell Lymphoma Genotyping by Alu — Polymerase Chain Reaction (2000) (2)
Abstract 2651: A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models (2017) (2)
Bendamustine in lymphomas: More to combine? (2007) (2)
Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models (2015) (2)
The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23 (2002) (2)
Long Term Outcome of Gastric MALT Lymphoma Patients Treated with Anti-Helicobacter (Antibiotic and Proton-Pump Inhibitor) Regimens. (2007) (2)
Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity (2020) (2)
Bacterial infection-driven lymphomagenesis (2022) (2)
Subgroups of Diffuse Large B-Cell Lymphoma (DLBCL) with Different Genomic Lesions and Clinical Course During Treatment with R-CHOP. (2009) (2)
A Phase II Trial to Investigate the Link with Infectious Agents in Ocular Adnexal Marginal Zone Lymphoma, Especially with Chlamydia Species, and the Antineoplastic Effects of Doxycycline (Ielsg#27) (2010) (2)
Abstract 2853: Development of novel preclinical models of secondary resistance to the anti-CD37 antibody drug conjugate (ADC) IMGN529/DEBIO1562 in diffuse large B-cell lymphoma (DLBCL) (2018) (2)
Pathologic diagnosis: molecular genetics (2013) (2)
Supplementum 216: Diagnosis and treatment of marginal zone lymphoma. (2016) (2)
The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas (2015) (2)
Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures (2019) (2)
Influence of radiotherapy on cardiac implantable electronic devices: a single center experience (2012) (2)
Gastric MALT lymphomas prospective LY03 randomised cooperative trial: preliminary results of the molecular follow-up (2001) (2)
Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation (2021) (2)
A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virus (2022) (2)
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type (2021) (2)
Genomic profiles of MALT lymphomas: variability across anatomic sites Running title: Genomic lesions in MALT lymphomas (2011) (1)
Abstract 3829: NEO1132 and NEO2734, novel dual bromodomain inhibitors of both BET and CREBBP/EP300, compared to single BET or CREBB/EP300 inhibitors in diffuse large B cell lymphoma (2019) (1)
In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas. (2006) (1)
lymphocytic leukemia to Richter syndrome Two main genetic pathways lead to the transformation of chronic (2013) (1)
Early analysis of toxicity and surgery in patients treated with cetuximab single agent followed by 5-fu, cetuximab and pelvic radiotherapy as neo-adjuvant treatment for operable, locally advanced rectal cancer (rc) (2007) (1)
SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL (2018) (1)
The Genome of Chronic Lymphocytic Leukemia (2010) (1)
The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma (2014) (1)
Genome-wide DNA proﬁling of marginal zone lymphomas identiﬁes subtype-speciﬁc lesions with an impact on the clinical outcome (2011) (1)
Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis (2010) (1)
Bone Marrow Pathology, fourth edition. Barbara Bain, David M. Clark and Bridget S. Wilkins. Wiley-Blackwell, Chichester, UK, January 2010, Hardcover edition, 630pp. ISBN: 9781405168250 (2010) (1)
Forodesine (Immucillin H, BCX-1777) Shows Activity on Mantle Cell Lymphoma Primary Cells (2008) (1)
The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response (2014) (1)
The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications (2022) (1)
Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling (2022) (1)
SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS) (2011) (1)
Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma (2014) (1)
Genome Wide-DNA Profiling of Richter’s Syndrome-Diffuse Large B-Cell Lymphoma (RS-DLBCL): Differences with De Novo DLBCL and Possible Mechanisms of Transformation from Chronic Lymphocytic Leukemia (CLL). (2008) (1)
A Phase II Study to Investigate the Prevalence of Infectious Agents in Ocular Adnexae Marginal Zone Lymphoma (Oamzl) and the Efficacy of Antibiotic Therapy (Ielsg#27 Trial) (2011) (1)
BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma (2014) (1)
Abstract 4793: Combinations containing the aza-anthracenedione pixantrone show preclinical activity in diffuse large B-cell lymphoma (2016) (1)
United we stand: Double targeting of CD79B and CD20 in diffuse large B‐cell lymphoma (2022) (1)
ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma (2016) (1)
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors (2023) (1)
SNP-Arrays Provide New Insights Into the Pathogenesis of Post-Transplant Diffuse Large B-Cell Lymphoma (PT-DLBCL). (2009) (1)
Myc controls IL-15-driven expansion and translational machinery of NK cells (2022) (1)
Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines. (2016) (1)
The NF-κB Pathway Is Targeted by Multiple Genetic Lesions In Splenic Marginal Zone Lymphoma (2010) (1)
The novel mTORC1/2 inhibitor PQR620 has in vitro and in vivo activity in lymphomas (2016) (1)
Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials. (1999) (1)
CLL 260 PROGNOSTIC VALUE OF ELEVATED POLYCLONAL SERUM FREE LIGHT CHAINS IN STAGE A CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS (2011) (1)
A prize-collecting Steiner tree application for signature selection to stratify diffuse large B-cell lymphoma subtypes (2018) (1)
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) (2010) (1)
Chronic myeloid leukemia treated with busulfan. (1996) (1)
IGHD3‐3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia (2010) (1)
SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups (2010) (1)
TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL (2016) (1)
A multicenter phase II study (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma (2011) (1)
Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors† †Electronic supplementary information (ESI) available: General procedures for the synthesis, characterization and biological evaluation of all reported compounds can be found in the ESI. See DOI: 10. (2020) (1)
Abstract 5179: The first in class FLI1 inhibitor TK-216 presents both in vitro and in vivo anti-tumor activity in lymphoma (2017) (1)
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS (2010) (1)
Abstract 4275: Analysis of gene and protein expression in lymphoma cell lines using multiple platforms (2018) (1)
Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas (2015) (1)
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. (2008) (1)
PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38) (2021) (1)
Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma (2019) (1)
Genome Wide-DNA Profiling of HIV-Related Non-Hodgkin Lymphomas: Implications for Disease Pathogenesis and Histogenesis. (2007) (1)
Retinal metastases treated with lapatinib (L) in a young HER2-positive breast cancer patient: Case report (2008) (1)
Abstract C097: Pyrrolo[2′,3′:3,4]cyclohepta[1,2-d][1,2]oxazoles: A new class of antimitotic agents (2019) (1)
Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features. (2009) (1)
MYC network mutations in high‐risk chronic lymphocytic leukaemia (2014) (1)
DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) (2017) (1)
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer (2018) (1)
Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy. (1996) (1)
Abstract C193: Combining ibrutinib with Chk1 inhibitors as a new therapeutic strategy for mantle cell lymphoma (2015) (1)
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma (2022) (1)
Bayesian Joint Estimation of CN and LOH Aberrations (2009) (1)
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma (2021) (1)
Session 4 : lymphoma genomics (2011) (1)
COMMONLY INACTIVATED BY DNA MUTATIONS AND DELETIONS IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (EMZL) (2008) (1)
568 The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM) (2014) (0)
Abstract B009: The histone deacetylase inhibitor pracinostat and its metabolite SB991 are active as single agents and in combination with 5-azacitidine in acute myeloid leukemia cells (2019) (0)
Recommended Procedures for Initial Staging and Follow-Up of Patients With Nongastric MALT Lymphoma (2017) (0)
889 IOA-244 is a non-ATP-competitive, highly selective, tolerable phosphoinositide 3-kinase delta inhibitor that directly targets solid tumours and breaks immune tolerance (2022) (0)
Author response for "STAT6 activation correlates with cerebrospinal fluid IL‐4 and IL‐10 and poor prognosis in Primary Central Nervous System Lymphoma" (2019) (0)
with other anti-lymphoma targeted agents The BTK inhibitor zanubrutinib ( BGB-3111 ) demonstrated synergies Version 2 HAEMATOL / 2018 / 214759 Haematologica Bertoni (2019) (0)
Abstract B041: PQR309-containing combinations show synergistic antilymphoma activity (2018) (0)
Histologic Transformation in Marginal Zone Lymphomas (2012) (0)
Abstract CT402: A phase I study of inotuzumab ozogamicin (IO) in combination with temsirolimus (T) in patients (pts) with relapsed or refractory (R/R) CD22-positive (pos) B-cell non-Hodgkin lymphomas (NHL) (2014) (0)
EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA (2019) (0)
cuRnet: an R package for graph traversing on GPU (2018) (0)
Correction to: cuRnet: an R package for graph traversing on GPU (2018) (0)
subtype-specific lesions with an impact on the clinical outcome Genome-wide DNA profiling of marginal zone lymphomas identifies (2011) (0)
Cancer and its management, sixth edition. Jeffrey Tobias and Daniel Hochhauser. Wiley-Blackwell, Chichester, UK, 2010, Paperback edition, 560pp., ISBN 978-1-4051-7015-4. (2011) (0)
Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax (2016) (0)
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia (2010) (0)
Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart (2011) (0)
An Improved Bayesian Method for DNA Copy Number Estimation (2007) (0)
Abstract B182: The novel tyrosine kinase inhibitors UJ26 and UJ30 are active in solid tumor and hematologic cancer cell lines (2018) (0)
Myc controls NK cell development, IL-15-driven expansion, and translational machinery (2023) (0)
Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma. (2012) (0)
as a comparative model for human (2019) (0)
Abstract 163: DNA methyltransferase modulation in lymphoma cells involves functional redundancy and maintains hypermethylation of selected regions (2020) (0)
Genome-Wide Analysis of DNA Copy Number in Multiple Myeloma Using High-Density SNP Arrays Reveals Clustering Patterns with Distinct Transcriptional Profiles. (2007) (0)
Abstract 2604: Characterization of the activity and the mechanism of action of the new retinoid derivative ST5589 in pre-clinical models of lymphomas: involvement of MYC and cell cycle genes (2014) (0)
PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL) (2022) (0)
66 Anti-proliferative activity of a PPAR gamma agonist is associated with changes in the expression of cell cycle and apoptosis related genes in human ovarian cancer cells (2004) (0)
Cyclin-Dependent Kinase Inhibitor Seliciclib Shows In Vitro Activity in Diffuse Large B Cell Lymphomas. (2006) (0)
SAKK 36 / 13 – Ibrutinib and bortezomib and ibrutinib maintenance for relapsed / refractory mantle cell lymphoma : an ongoing trial (2018) (0)
Session 8: pathology and clinicopathological correlations 077 THE RELIABILITY OF IMMUNOHISTOCHEMICAL ANALYSIS OF TUMOR MICROENVIRONMENT IN FOLLICULAR LYMPHOMA; A VALIDATION STUDY FROM THE LUNENBURG LYMPHOMA BIOMARKER CONSORTIUM (LLBC) (2011) (0)
Abstract 796: The BTK inhibitor BGB-3111 is synergistic with other anti-lymphoma targeted agents (2018) (0)
DNA binding, inhibition of Sp1 binding and cellular uptake of MTM analogs (2011) (0)
Abstract 1879: A novel implantable device to in vivo assess anti-cancer agents (2022) (0)
3 Pathogenesis of ocular adnexal lymphoma (2010) (0)
Microarray Datasets Using a Comprehensive Collection of Signatures for Different T Cell Responses , Identification of T Cell-Restricted Genes , and Sallusto (2005) (0)
recognition of ALK-negative anaplastic large-cell lymphoma Identification of a 3-gene model as a powerful diagnostic tool for the (2012) (0)
Book review: Understanding Leukemias, Lymphomas and Myelomas, Second Edition. Tariq I. Mughal, John M. Goldman and Sabena T. Mughal. Informa Healthcare, London, UK, 2010, Hardcover ISBN 9781841846941, 1841846945, 164pp. (2012) (0)
IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance (2023) (0)
Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia (2016) (0)
Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas. (2005) (0)
Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. (1997) (0)
57 High-resolution genomic profiling of 533 B-cell lymphomas defines distinct tumor signatures, genomic aberrations correlated with outcome and pathogenetic subgroups (2010) (0)
neuro-oncology 897P CLINICAL FEATURES, OUTCOME AND LATE EFFECTS IN MALIGNANT INTRACRANIAL GERM CELL TUMORS. (2006) (0)
Role of canonical and non-canonical signaling in fibroblast to cancer-associated fibroblast transition (0)
Abstract 1894: Identification of novel OTX015-containing combinations for lymphoma treatment (2018) (0)
Clinical-Biological Characterization of Variant B Chronic Lymphocytic Leukemia, Characterized by a Mantle Cell Lymphoma-Like Immunophenotype, t(11;14)(q13;q32) Negative. (2009) (0)
The intermediate governance as a tool of territorial homogeneity: The case of Metropolitan Area of Bologna (2018) (0)
The BET bromodomain inhibitor (BET-i) BAY 1238097: Mechanism of action and pre-clinical activity in diffuse large B-cell lymphoma (DLBCL) (2016) (0)
Data describing the effects of potassium channels modulators on outward currents measured in human lymphoma cell lines (2020) (0)
An epigenetic signature in CD19-CAR T cells predicts clinical outcome. (2021) (0)
Targeted Therapy in Translational Cancer ResearchApostolia‐MariaTsimberidouRazelleKurzrockKenneth C.Anderson. Wiley‐Blackwell, 2016, 400pp., Ebook (130 euros) or Hardcover (144 euros) (2019) (0)
The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL) (2015) (0)
DNA Damage Response Inhibitor Combinations Exert SynergisticAntitumorActivity inAggressive B-Cell Lymphomas (2019) (0)
Abstract A14: The RNA helicase DDX21 cooperates with ETS1 and FLI1 in cell cycle and RNA processing (2022) (0)
SIMULTANEOUS BET/CREBBP/EP300 TARGETING APPROACH COMPARED TO SINGLE BET OR CREBBP/EP300 INHIBITION IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (2019) (0)
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial (2022) (0)
Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome (2008) (0)
Abstract 906: Development of novel preclinical models of secondary resistance downstream B cell receptor in marginal zone lymphoma (2018) (0)
LYMPHOID NEOPLASIA Identi ﬁ cation of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts (2015) (0)
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia (2012) (0)
Hematological Oncology: further ahead (2008) (0)
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma (2022) (0)
Genome-wide analysis of DNA copy number changes in multiple myeloma using high-density SNP arrays (2007) (0)
A phase I-II and pharmacodynamic (PD) study of the combination of the proteasome inhibitor bortezomib (B) and paclitaxel (P) in patients with taxane-sensitive solid tumors. (2006) (0)
Pathogenesis of ocular adnexal lymphoma (2010) (0)
Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas. (2023) (0)
Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models (2020) (0)
LYMPHOID NEOPLASIA DNA methylation pro ﬁ ling identi ﬁ es two splenic marginal zone lymphoma subgroups with different clinical and genetic features (2015) (0)
Abstract 4575: Three-gene diagnostic classifier for ALK negative ALCL (2012) (0)
Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α–STAT3 Axis (2022) (0)
Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway (2011) (0)
Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts (2014) (0)
Referee acknowledgement for 2017 (2018) (0)
Abstract B76: Evaluation of the novel BET Bromodomain inhibitor BAY 1238097 in lymphoma models identifies EZH2 and MYD88 mutations as potential biomarkers and the bases for combinations (2015) (0)
Chronic lymphocytic leukemia subset expressing mutated IGHV3-23 has a peculiar clinical and biological features (2010) (0)
Unravelling transformation of Follicular Lymphoma to Diffuse Large B- Cell Lymphoma. (2018) (0)
MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma) (2013) (0)
LYMPHOID NEOPLASIA Deregulation of ETS 1 and FLI 1 contributes to the pathogenesis of diffuse large B-cell lymphoma (2013) (0)
Abstract 5215: Inhibition of PIM kinases targets synthetic vulnerabilities and enhances antigen presentation in B cell lymphoma (2020) (0)
Multivariate Analysis of Prognostic Factors in CLL: A Study on 431 Patients Showing Usefulness of Novel Biological and Old Clinical Parameters in Predicting Shorter Survival: An Italian Multicentric Study (2008) (0)
Abstract 4206: EUD-GK-001 is a novel kinase inhibitor within vitroanti-lymphoma activity (2020) (0)
Marginal-Zone Lymphomas. Reply. (2022) (0)
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines (2019) (0)
Genome‐wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas (2014) (0)
Emerging Cancer Therapeutics: Lymphomas. John Sweetenham (guest editor). Demos Medical Publishing, 2012, New York, NY, USA. Hardcover edition, 389 pp., USD 85.00 (2014) (0)
Abstract A117: An integrated phosphoproteomic approach to dissect the mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas (2015) (0)
Identification and validation of novel and annotated LncRNAs in canine B-cell lymphoma by RNA-seq (2017) (0)
Publisher Correction: HMGA1-pseudogene7 transgenic mice develop B cell lymphomas (2021) (0)
Abstract 2575: Avanbulin, the active moiety of the tumor checkpoint controller lisavanbulin (BAL101553), has anti-lymphoma activity (2022) (0)
Identification of New Recurrent Multiple Small Interstitial Deletions Affecting Genes Coding for Kinases in Chronic Lymphocytic Leukemia (CLL): a New Pathogenic Mechanism?. (2009) (0)
546 A novel aureolic acid antibiotic analogue has potent anti-proliferative activity and induces multiple changes in gene expression in ovarian cancer cells (2004) (0)
Abstract A129: Novel histone deacetylase inhibitors ITF-A and ITF-B exhibit efficacy in preclinical models of mature B-cell lymphomas. (2013) (0)
Application of genomic real-time PCR to characterise 11q deletions in mantle cell lymphoma and chronic lymphocytic leukaemia (2001) (0)
Abstract 3279: Dual inhibition of EZH2 and histone deacetylases for the treatment of lymphomas with epigenetic aberrations (2022) (0)
A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study (2019) (0)
Identification of molecular classifiers and key signalling networks in T-cell lymphoproliferative disorders through gene expression profiling meta-analyses (2011) (0)
Correction to: cuRnet: an R package for graph traversing on GPU (2018) (0)
Abstract 492: Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B cell lymphoma models (2023) (0)
IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES (2019) (0)
A phase II trial addressing the prevalence of chlamydial infection and eradication efficacy of antibiotic therapy in marginal zone lymphoma (OAMZL) and other lymphoproliferative disorders of the ocular adnexae (LPDOA) (2010) (0)
ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma (2021) (0)
IL-1α secreted by subcapsular sinus macrophages promotes melanoma metastasis in the sentinel lymph node by upregulating STAT3 signaling in the tumor (2021) (0)
THE TRANSCRIPTION FACTOR FLI1 SUSTAINS RELEVANT BIOLOGICAL PATHWAYS AND DRIVES ONCOGENES THAT PROMOTE CELL GROWTH IN DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (2019) (0)
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib (2023) (0)
Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL) (2010) (0)
MALT lymphoma: extranodal marginal zone B-cell lymphoma of MALT (2013) (0)
The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship (2010) (0)
OVERALL POOR PROGNOSIS OF LEUKEMIC LYMPHO- PROLIFERATION WITH MANTLE CELL PHENOTYPE MANTLE CELL LYMPHOMA: CHROMOSOMAL ABERRA- TIONS, PROLIFERATON AND CYCLIN D1 TRANSCRIPTS IN RELATION TO CLINCIAL OUTCOME GENE EXPRESSION TO IDENTIFY NEW GENES IN MANTLE CELL (2005) (0)
Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent (2023) (0)
Construction of a chromosome 11q22–23 BAC/PAC contig to characterize deletions in lymphoproliferative disorders (2001) (0)
Referee Acknowledgement for 2013 (2014) (0)
Abstract 5528: The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors (2014) (0)
lymphoma biology 273 EXONIC MUTATIONS ARE COMMONLY FOUND IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA AND FAMILY MEMBERS OF WM PATIENTS WITH HYPER-IGM SYNDROME (2008) (0)
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo. (2022) (0)
Molecular and Transcriptional Characterization of the Novel 17p11.2-p12 Chromosome Amplification in Multiple Myeloma. (2007) (0)
Lymphoma: MALT lymphoma and other marginal zone lymphomas (2007) (0)
A Multicentre Phase II Trial Testing Gemcitabine in the Treatment of Patients with Newly Diagnosed, Relapsed or Chemotherapy Resistant Mantle Cell Lymphoma: SAKK 36/03. (2007) (0)
Knowledge and social planning. A case study: the Bologna Observatory on Social Needs (2016) (0)
Abstract 1017: The BRD-inhibitor OTX015 affects proliferation and gene expression of cells derived from mature lymphoid neoplasms. (2013) (0)
Editorial: New insights into the mechanisms of resistance to anti-cancer drugs (2022) (0)
Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome. (2009) (0)
Abstract 380: The dual PI3K/MTOR inhibitor PQR309 is active in mature B cell lymphoma cell lines bearing resistance to the PI3K-delta inhibitor idelalisib and specific gene expression features (2016) (0)
Molecular Oncology: B-cell chronic lymphocytic leukemia (2013) (0)
Physiopathogenesis of Hematological Cancer. Estela MariaNovak and Eduardo MagalhãesRego‬. Bentham Science Publishers, Sharjah, 2012, U.A.E. Ebook/Print-on-Demand, 255pp., USD 109/131 (2014) (0)
A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) (2021) (0)
ETS1 PHOSPHORYLATION AT THR38 (PETS1) IS ASSOCIATED WITH CELL OF ORIGIN (COO), CELL CYCLE ACTIVATION, AND INFERIOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (2017) (0)
Abstract PO-07: The FLI1 direct target ASB2 promotes NF-KB pathway activation in diffuse large B-cell lymphoma of the germinal center B-cell type (2020) (0)
Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience. (2007) (0)
Abstract 799: The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent (2018) (0)
Recurrent 11q24.3 Gain Contributes to the Pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL) by Deregulating ETS1 and FLI1 (2011) (0)
Abstract 1701: The novel anti-CD205 antibody drug conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL) (2017) (0)
Abstract 739: The MEK-inhibitor pimasertib in B-cell lymphomas: Evaluation of the pre-clinical activity as single agent or in combination and identification of biomarkers of response (2014) (0)
THE FIRST‐IN‐CLASS ETS INHIBITOR TK‐216 INTERFERES WITH ETS TRANSCRIPTION FACTORS AND SYNERGIZE WITH LENALIDOMIDE IN LYMPHOMA (2019) (0)
In vitro anti‐lymphoma activity of the first‐in‐class pan‐NOTCH transcription inhibitor CB‐103 (2022) (0)
Abstract 2655: The GPCR OR13A1 is essential for lymphoma cells (2022) (0)
The Cytofluorimetric/FISH Diagnostic Approach Define a B-Cell Variant-CLL with Peculiar Clinico-Biological Features. (2007) (0)
behavior subset refractory to single-agent cladribine and with more aggressive Hairy cell leukemias with unmutated IGHV genes define the minor (2013) (0)
PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) (2016) (0)
Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment (2022) (0)
Abstract 4735: The histone deacetylase inhibitor pracinostat modulates the transcriptome of diffuse large B-cell lymphoma cells and is active in combination with several targeted agents (2019) (0)
Patterns of global DNA methylation identify early stage (Binet A) CLL patients with higher risk of disease progression (2012) (0)
wild-type chronic lymphocytic leukemia TP53 associates with fludarabine chemorefractoriness in BIRC3 Disruption of (2012) (0)
THE NONCODING RNA GECPAR IS INVOLVED IN WNT SIGNALING AND HAS TUMOR‐SUPPRESSOR ACTIVITY IN DIFFUSE LARGE B CELL LYMPHOMA (2019) (0)
outcome Analysis Of Diffuse Large B-cell Lymphoma (dlbcl) In Hiv-infected And Immunocompetent (ic) Patients: The Swiss Hiv Cohort Study (shcs) : 218 (2015) (0)
Abstract A05: Olfactory receptors as a new therapeutic target in lymphomas (2022) (0)
A systematic review of contemporary phase I trials in patients with lymphoma. (2022) (0)
Single Cell RNA-Seq of Extranodal Marginal Zone Lymphoma (MZL) Identifies Site-Specific and Shared Features in Both B and T Cell Components (2022) (0)
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms (2023) (0)
195 POSTER Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies (2008) (0)
ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL‐LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (2017) (0)
Candidate Genes for the 11Q Abnormality in Chronic Lymphocytic Leukaemia (CLL) (2002) (0)
The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL) (2016) (0)
Integrative genomics based on microarrays analyses reveals a correlation between allelic imbalances and gene expression patterns in multiple myeloma (2008) (0)
High Resolution Array-CGH Provides New Insights Into the Prognosis of Chronic Lymphocytic Leukemia (CLL): Is 8p Loss Worse Than 17p Loss?. (2009) (0)
Abstract 552: Multi-scale omics integration using parallel heatmap clustering for the systemic analysis and biomarker discovery of drug sensitivity in lymphoma cell lines (2017) (0)
Large Genomic Aberrations Are Independent Prognosticators of A Shorter Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia (CLL) Patients with A Normal FISH (2012) (0)
Lecture Notes: Oncology, 3rd Edition. Mark Bower and Jonathan Waxman. Wiley-Blackwell, 2016, Ebook/Paperback, 352 pp., Prices starting from 23.80 euros (2017) (0)
MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA (2019) (0)
Where Do We Stand in the Genomics of Lymphomas (2013) (0)
COMBINATORIAL SCREENING OF THE PI3K INHIBITOR COPANLISIB IN T CELL LYMPHOMAS (2017) (0)
Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping (2000) (0)
RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis (2021) (0)
Genomic aberrations aff ecting the outcome of immunodefi ciency-related diff use large B-cell lymphoma (2012) (0)
Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP (2008) (0)
A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers (2022) (0)
Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma (2014) (0)
The Role of FLI1 in mRNA Splicing and rRNA Processing of Diffuse Large B Cell Lymphoma (DLBCL) (2017) (0)
HTGQC and shinyHTGQC: an R package and shinyR application for quality controls of HTG EDGE-seq protocols (2022) (0)
Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia. (2007) (0)
Predicting outcome in dogs with diffuse large B-cell lymphoma with a novel immune landscape signature (2023) (0)
Abstract 1654: The small molecule YK-4-279 shows anti-lymphoma activity in pre-clinical models (2015) (0)
[Supradiaphragmatic right-sided space-occupying lesion]. (1997) (0)
Abstract 4796: EG-011 is a novel small molecule within vitroandin vivoanti-tumor activity against lymphoma (2019) (0)
OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE (2021) (0)
Abstract 2219: STAT3 network dissection in ALK positive Anaplastic Large Cell Lymphomas (2014) (0)
Abstract LB-269: IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies (2018) (0)
IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin (2010) (0)
The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21 (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Francesco Bertoni?

Francesco Bertoni is affiliated with the following schools:

Università della Svizzera italiana
University of Milan
ETH Zurich
University of Bern
University of Zurich

Francesco Bertoni's Academic­Influence.com Rankings

Francesco Bertoni's Degrees

Why Is Francesco Bertoni Influential?

Francesco Bertoni's Published Works

Published Works

What Schools Are Affiliated With Francesco Bertoni?

Francesco Bertoni's AcademicInfluence.com Rankings